You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 21, 2024

Details for Patent: 11,918,623

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,918,623 protect, and when does it expire?

Patent 11,918,623 protects ZEPBOUND and ZEPBOUND (AUTOINJECTOR) and is included in one NDA.

This patent has forty-one patent family members in thirty-two countries.

Drugs Protected by US Patent 11,918,623

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eli Lilly And Co	ZEPBOUND	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-007	Mar 28, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION	⤷ Subscribe
Eli Lilly And Co	ZEPBOUND	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-008	Mar 28, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION	⤷ Subscribe
Eli Lilly And Co	ZEPBOUND	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-009	Mar 28, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION	⤷ Subscribe
Eli Lilly And Co	ZEPBOUND	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-010	Mar 28, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION	⤷ Subscribe
Eli Lilly And Co	ZEPBOUND	tirzepatide	SOLUTION;SUBCUTANEOUS	217806-011	Mar 28, 2024		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG/M2 OR GREATER (OBESITY), OR 27 KG/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 11,918,623

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	115542	⤷ Subscribe
Australia	2019289110	⤷ Subscribe
Australia	2022279524	⤷ Subscribe
Brazil	112020023452	⤷ Subscribe
Canada	3103469	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.